TB-500 (thymosin beta-4) Dosage: What the Evidence Says (2026)
Not FDA-approved
Name used for thymosin beta-4 and for a 7-amino-acid fragment of it. Not approved; no human dose data for the fragment.
Also called: thymosin beta-4, Tβ4, Ac-LKKTETQ
Regulatory status (US)
Not approved by the FDA for any use. FDA removed it from its "significant safety risk" compounding list in April 2026 after the nomination was withdrawn, and an FDA advisory committee voted in favor of allowing pharmacy compounding in July 2026, against the recommendation of FDA staff. On October 30, 2026, HHS published a draft policy saying it does not intend to take enforcement action against state-licensed pharmacies that compound it for a named patient with a prescription, under listed conditions and routes. That is not an FDA approval and says nothing about safety or effectiveness. The draft policy names the acetate form for injection under the skin or into muscle.
What it is
Thymosin beta-4 is a natural 43-amino-acid protein involved in cell movement and repair. The FDA's "TB-500" is a short fragment of it (Ac-LKKTETQ). Sellers use the name for both, so what is in a vial is uncertain.
Dosage
TB-500 reconstitution calculator
Enter your vial and your prescribed dose to see the units on a U-100 syringe.
What human studies show
- TB-500 fragment: no human exposure data (FDA).
- Full-length thymosin beta-4 was tested as eye drops for dry eye; the ARISE-3 trial missed its main goals.
Safety
- No established human dose for the fragment.
Questions
- Is TB-500 FDA-approved?
- Not approved by the FDA for any use. FDA removed it from its "significant safety risk" compounding list in April 2026 after the nomination was withdrawn, and an FDA advisory committee voted in favor of allowing pharmacy compounding in July 2026, against the recommendation of FDA staff. On October 30, 2026, HHS published a draft policy saying it does not intend to take enforcement action against state-licensed pharmacies that compound it for a named patient with a prescription, under listed conditions and routes. That is not an FDA approval and says nothing about safety or effectiveness. The draft policy names the acetate form for injection under the skin or into muscle.
- What dose of TB-500 has been studied?
- There is no established human dose. TB-500 fragment: no human exposure data (FDA). Full-length thymosin beta-4 was tested as eye drops for dry eye; the ARISE-3 trial missed its main goals.
- How many units is my TB-500 dose?
- Divide the mg in the vial by the mL of bacteriostatic water to get mg/mL, divide your dose in mg by that, and multiply by 100 for units on a U-100 syringe. The calculator on this page does it and draws the syringe.
Related
The first 29 amino acids of GHRH. Former brand Geref was withdrawn in 2009; no product is marketed today.
BPC-15715-amino-acid peptide studied mostly in animals. Not approved; no established human dose.
GHK-Cu (copper peptide)Copper-binding tripeptide used in skin care. Topical studies only; no human injection data.
KLOW and GLOW blendsSeller-defined mixes of GHK-Cu, BPC-157, TB-500 (GLOW) plus KPV (KLOW). No human data for any blend.
Sources
- FDA: Certain bulk drug substances for compounding that may present significant safety risks
- Federal Register (public inspection) 2026-07361: peptide category changes
- PharmExec: FDA advisory committee votes to loosen restrictions on peptides (Jul 2026)
- Federal Register 2026-22192: HHS draft enforcement discretion policy for 503A compounding of certain peptides (Oct 30, 2026)
- ClinicalTrials.gov NCT03937882: RGN-259 (thymosin beta 4) eye drops, ARISE-3
- FDA 510(k) K212499: BD insulin syringes for U-100 insulin
Last checked 2026-11-16. How we pick and check sources: methodology.